In the Media

InMed CEO says ‘tremendous potential’ for its cannabinoid-based therapy to treat glaucoma

InMed Pharmaceuticals Inc (CSE:IN) (OTCMKTS:IMLFF) CEO Eric Adams sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco.

In this interview, Mr. Adams speaks about InMed’s focus on the therapeutic development of rare cannabinoids to treat serious diseases.  Mr. Adams talks about the progress of INM-755, the company’s lead program in epidermolysis bullosa, which has begun Phase 1 clinical trials in healthy volunteers. He also talks about InMed’s glaucoma program and the potential of INM-088 to proactively protect neurons and reduce intraocular pressure.

Source: Proactive Investors

Share this post

Latest Media News